MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Neurocrine Biosciences Inc

Fechado

SetorSaúde

102.61 -5.25

Visão Geral

Variação de preço das ações

24h

Atual

Mín

102.27

Máximo

107.9

Indicadores-chave

By Trading Economics

Rendimento

-27M

103M

Vendas

5.6M

628M

P/E

Médio do Setor

33.617

63.778

EPS

1.69

Margem de lucro

16.425

Funcionários

1,800

EBITDA

-39M

152M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+53.74% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-3.8B

11B

Abertura anterior

107.86

Fecho anterior

102.61

Sentimento de Notícias

By Acuity

50%

50%

180 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Neurocrine Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

28 de jan. de 2025, 00:03 UTC

Ações em Alta

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

13 de ago. de 2024, 11:30 UTC

Principais Notícias

S&P 500 Futures Climb In Premarket Trading; On Holding, Western Midstream Ptrs Lag

Comparação entre Pares

Variação de preço

Neurocrine Biosciences Inc Previsão

Preço-alvo

By TipRanks

53.74% parte superior

Previsão para 12 meses

Média 164.5 USD  53.74%

Máximo 192 USD

Mínimo 138 USD

Com base em 22 analistas de Wall Street que oferecem metas de preço de 12 meses para Neurocrine Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

22 ratings

17

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

106.49 / 110.685Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

180 / 386 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.